Previous 10 | Next 10 |
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) , a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina, presented a poster today at the ann...
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) , a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting a poster a...
PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that members of its management team...
PURCHASE, N.Y., April 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that the company would be participa...
Gainers: Protalix BioTherapeutics (PLX) +74%. Aterian (ATER) +62%. Dingdong Limited (DDL) +40%. Jumia Technologies (JMIA) +30%. Twitter (TWTR) +27%. Takung Art (TKAT) +24%. Gracell Biotechnologies (GRCL) +22%. Cognition Therapeutics (CGTX) +21%. Poema Global Holdings (PPGH) +20%. Biophytis (B...
Cognition Therapeutics, Inc. (CGTX) Q4 2021 Earnings Call March 30, 2022 08:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer Jim O'Brien - Chief Financial Officer Tony Caggiano - Chief Medical Officer and Head of R...
Cognition Therapeutics press release (NASDAQ:CGTX): FY GAAP EPS of -$3.13 misses by $2.64. Cash and cash equivalents on December 31, 2021 was $54.7 million. For further details see: Cognition Therapeutics GAAP EPS of -$3.13 misses by $2.64
- Well capitalized from $52 million IPO and $169 million in grant funding - - Established clinical program in Alzheimer’s disease enhanced by new DLB study and dry AMD program - - Conference call and live audio webcast scheduled for Wednesday, March 30 at 8:00 a.m. ET -...
PURCHASE, N.Y., March 22, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the...
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) , a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting results fr...
News, Short Squeeze, Breakout and More Instantly...
Cognition Therapeutics Inc. Company Name:
CGTX Stock Symbol:
NASDAQ Market:
Cognition Therapeutics Inc. Website:
2024-07-29 17:15:02 ET Cantor Fitzgerald analyst issues NEUTRAL recommendation for CGTX on July 29, 2024 04:08PM ET. CGTX was trading at $1.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recom...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.3% to $111.59 on volume of 240,827,673 shares Lipella Pharmaceuticals Inc. (LIPO) rose 122.5% to $0.8992 on volume of 193,926,302 shares PROSHARES TRUST (SQQQ) fell 0.5% to $9.05 on volume of 150,372,371...
- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - Significant Changes in Neurofila...